Bafisontamab (EMB-01) is a bispecific antibody targeting EGFR and cMET with antitumor activity.
Bafisontamab (EMB-01) induces significantly stronger anti-tumor activity in PDX and CDX tumor models than that of anti-EGFR mAb or anti-cMet mAb alone. Bafisontamab shows significant anti-tumor activity in anti-EGFR mAb resistant tumor model[1].
References:
[1]. Ren F, et al. EMB-01: An innovative bispecific antibody targeting EGFR and cMet on tumor cells mediates a novel mechanism to improve anti-tumor efficacy. Cancer Research, 2020, 80(16_Supplement): 528-528.